Sana Biotechnology (SANA) Jefferies Global Healthcare Conference 2026 summary

Strategic platforms and technology focus

• Two core platforms: hypoimmune allogeneic cell therapy and in vivo gene delivery, both advancing toward clinical trials this year.

• Hypoimmune platform aims for a functional cure for type 1 diabetes by evading immune rejection, with promising preclinical and early human data.

• In vivo CAR T platform targets direct genetic modification of T cells, with two assets nearing clinical entry and a focus on best-in-class therapy.

• Both platforms are expected to generate initial human data within 12 months, with rapid clinical development anticipated if early results are positive.

• Manufacturing advances include a genomically stable, gene-modified GMP master cell bank, with technology transfer to GMP facilities underway.

Clinical development plans and timelines

• IND filing and phase I trial for type 1 diabetes targeted for as early as 2026, with buffer time built into guidance.

• Phase I will enroll adults over 18, with plans to expand to younger and older populations as data matures.

• Study design focuses on all-comer inclusion, avoiding restrictive criteria used by competitors.

• Key phase I endpoints: immune evasion, insulin independence, and generalizability across patients, with early signals expected within weeks to months.

• Pivotal trial may require around 50 patients, with regulatory discussions and commercial process development ongoing in parallel.

Risk management and regulatory considerations

• Manufacturing and technology transfer challenges acknowledged, but progress and contingency plans are in place.

• Long-term safety risks, such as tumorigenicity, will be monitored post-approval, with a 15-year follow-up required for gene-modified therapies.

• Early data will be disclosed when material, with a balance between investor updates and peer-reviewed scientific presentations.

• Regulatory pathway expected to involve a small registration study with extensive post-marketing surveillance.